Annexon Biosciences is leading the development of therapeutic products that halt the progression of complement-mediated neurodegeneration. Annexon’s antibody pipeline is based on breakthrough research involving the classical complement pathway and the unique role of its initiating molecule, C1q, in the loss of nerve connections and inflammation.